Company News in the Life Science Industry

»

Reset 

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ -- For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

EAST HANOVER, N.J., Dec. 10, 2017 /PRNewswire/ -- Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah(TM) (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017
Related companies:  Genomics Institute of the Novartis Research Foundation

New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

TAMPA, Fla., Dec. 10, 2017 /PRNewswire/ -- A new article published today in The New England Journal of Medicine... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017

Medivir Announces Janssen Decision to Terminate its Simeprevir License Effective June 2018

STOCKHOLM, Sweden, Dec.10, 2017 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen's assessment of market demand. The termination of the license... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017

PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017

WALTHAM, Mass., Dec. 10, 2017 /PRNewswire/ -- PharmaEssentia USA, a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of Ropeginterferon alfa-2b from the ongoing, long-term, follow-up trial CONTINUATION-PV (CONTI-PV) for patients with... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

CAMBRIDGE, Mass., Dec. 10, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new data from its ongoing Phase 1 clinical trial of avapritinib (formerly... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017
Related companies:  Blueprint Medicines

The Emirates Pathology Society (EPS):  Earlier Diagnoses of Cancer, Better Survival Rates & Improved Quality of Life Through Next-Generation Sequencing (NGS)

DUBAI, UAE, December 10, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 10 Dec 2017

Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies

ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ -- Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality... Read more ››

By: PR Newswire Association LLC. - 10 Dec 2017

IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

NORTH CHICAGO, Ill., Dec. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  AbbVie Inc.

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

ATLANTA and RARITAN, N.J., Dec. 9, 2017 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with IMBRUVICA(®) (ibrutinib). The extended follow-up data demonstrated... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017

Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

SEATTLE, Dec. 9, 2017 /PRNewswire-USNewswire/ -- Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017

uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting

Read more ››
By: Nasdaq / GlobenewsWire - 09 Dec 2017
Related companies:  uniQure N.V.

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication

SAN RAFAEL, Calif., Dec. 9, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  BioMarin Pharmaceutical Inc.

IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients

NORTH CHICAGO, Ill., Dec. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the RESONATE(TM)-2 study (PCYC-1115/1116), which found that previously-untreated chronic lymphocytic leukemia/small lymphocytic lymphoma... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  AbbVie Inc.

ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017

REDWOOD CITY, Calif., Dec. 9, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today released additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in non-small cell lung cancer (NSCLC).

Read more ››
By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  Armo BioSciences, Inc.

New Therapies Improve Outlook for Bleeding and Clotting Disorders

ATLANTA, Dec. 9, 2017 /PRNewswire-USNewswire/ -- In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017

St. Jude gene therapy improves immunity in babies with 'bubble boy' disease

ATLANTA, Dec. 9, 2017 /PRNewswire/ -- Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  St. Jude Children's Research Hospital

Bioengineering and Specialized Therapies Yield Results for Rare and Challenging Blood Diseases

ATLANTA, Dec. 9, 2017 /PRNewswire-USNewswire/ -- In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies for hard-to-treat blood disorders including... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017

Seno Medical Instruments Announces New Data Demonstrating That Imagio(TM) Opto-Acoustic Breast Imaging System Delivers Critical Diagnostic and Prognostic Information About Tumor Subtypes

SAN ANTONIO, Dec. 8, 2017 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic (OA/US) imaging to differentiate benign from malignant masses, reported clinical data from their clinical study demonstrating that... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2017
Related companies:  Seno Medical Instruments, Inc.

New Best Practices, LLC Report Provides Window into Future Trends for Digital Marketing Budget, Staffing and Performance Measurement

CHAPEL HILL, N.C., Dec. 8, 2017 /PRNewswire/ -- Pharmaceutical and medical device companies are increasingly using digital engagement channels to more effectively communicate with their customers.

Read more ››
By: PR Newswire Association LLC. - 09 Dec 2017
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 40,000 companies